| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044741633 |
| P356 | DOI | 10.1038/TPJ.2014.47 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/tpj.2014.47 |
| P698 | PubMed publication ID | 25156214 |
| P50 | author | Reo Tanoshima | Q80165252 |
| P2093 | author name string | S Ito | |
| W J Ungar | |||
| H F Burnett | |||
| P Madadi | |||
| W Chandranipapongse | |||
| P2860 | cites work | The Asia-Pacific consensus on ulcerative colitis. | Q37725083 |
| Pharmacogenetic testing: time for clinical practice guidelines | Q37867481 | ||
| Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines | Q38024710 | ||
| Evaluation of direct medical costs of hospitalization for febrile neutropenia | Q39916702 | ||
| Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity | Q40691808 | ||
| Variations by specialty in physician ratings of the appropriateness and necessity of indications for procedures | Q41002575 | ||
| Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update | Q43221642 | ||
| Phenotypic and Genotypic Analysis of Thiopurine S-Methyltransferase Polymorphism in the Bulgarian Population | Q43929309 | ||
| Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation | Q44007016 | ||
| Diagnosis and treatment of autoimmune hepatitis | Q44080061 | ||
| Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia | Q46398603 | ||
| Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 - *24). | Q46425354 | ||
| American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease | Q46985858 | ||
| Guidelines for the management of inflammatory bowel disease in adults | Q22242049 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada | Q24563151 | ||
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing | Q24632749 | ||
| Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy | Q28269559 | ||
| Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance | Q28307567 | ||
| Panellist consistency in the assessment of medical appropriateness | Q33571766 | ||
| Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues | Q33932189 | ||
| Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review | Q33937816 | ||
| Diagnosis and management of autoimmune hepatitis | Q34118165 | ||
| Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey | Q34249718 | ||
| Clinical pharmacology and pharmacogenetics of thiopurines | Q34782066 | ||
| Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? | Q35857878 | ||
| Guidelines for prescribing azathioprine in dermatology. | Q35987914 | ||
| Personalized medicine: is it a pharmacogenetic mirage? | Q36336007 | ||
| Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia | Q37388537 | ||
| Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. | Q37506748 | ||
| P433 | issue | 6 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 493-502 | |
| P577 | publication date | 2014-08-26 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents | |
| P478 | volume | 14 |
| Q59812730 | Associations between the R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis |
| Q39183771 | Biomarkers-A General Review |
| Q36284285 | Comparison of 6-mercaptopurine with 6-thioguanine for the analysis of thiopurine S-methyltransferase activity in human erythrocyte by LC-MS/MS. |
| Q38287641 | Ethical perspectives on translational pharmacogenetic research involving children |
| Q36328317 | Guideline appraisal with AGREE II: Systematic review of the current evidence on how users handle the 2 overall assessments |
| Q50319654 | Guideline appraisal with AGREE II: online survey of the potential influence of AGREE II items on overall assessment of guideline quality and recommendation for use. |
| Q46518961 | Pharmacogenomic testing and response to warfarin |
| Q50054064 | Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. |
| Q33876453 | Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders |
| Q38417177 | Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. |
| Q42801167 | Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia. |
| Q35971977 | Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review |
Search more.